The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment

Inclusion Criteria Concurrent Medication: Allowed: * Ganciclovir (provided drug was administered for at least 14 days prior to study entry, and the HSV isolate exhibits resistance against acyclovir). * Other medication considered necessary for patient's welfare, at the discretion of the investigator. Patients must have: * HIV infection or AIDS. * Mucocutaneous HSV infection with at least one clinically evaluable lesion. * Prior acyclovir without clinical benefit. * Life expectancy of at least 3 months. * Consent of parent or guardian if less than 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Known hypersensitivity to the study drug. * Any medical, psychiatric, or other condition that would preclude study compliance. * Incapable of self administration of medication or presence of a care provider administering medication. Concurrent Medication: Excluded: * Intravenous foscarnet for current episode of HSV. * Acyclovir, interferon, or any investigational drug that might have anti-HSV activity (e.g., 256U87, HPMPC, BVDaraU, trifluridine). Patients with the following prior condition are excluded: Previous participation in the study. Prior Medication: Excluded: * Intravenous foscarnet within 2 months prior to study entry.